Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx Head and Neck 3 Mins Read10 Molecule, RRx-001, has received fast track designation from the FDA. RRx-001 is a designer molecule with direct anti-inflammatory activity and…
Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx Head and Neck 20 Mins Read4 iFrame is not supported! Molecule RRx-001 Receives Fast Track Designation From the FDA – EpicentRx By Tony Reid, MD, PhD,…
REPLATINUM Phase III Trial Update [2022] Small Cell Lung Cancer 6 Mins Read3 REPLATINUM Phase III Update [2022] What is The Phase III REPLATINUM Clinical Trial In Small Cell Lung Cancer (SCLC)? Interesting…
